Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy

Despite progress in the treatment of acute lymphoblastic leukemia (ALL), T-cell ALL (T-ALL) has limited treatment options, particularly in the setting of relapsed/refractory disease. Using an unbiased genome-scale CRISPR-Cas9 screen we sought to identify pathway dependencies for T-ALL which could be...

Descripción completa

Detalles Bibliográficos
Autores principales: Pikman, Yana, Ocasio-Martinez, Nicole, Alexe, Gabriela, Dimitrov, Boris, Kitara, Samuel, Diehl, Frances F., Robichaud, Amanda L., Conway, Amy Saur, Ross, Linda, Su, Angela, Ling, Frank, Qi, Jun, Roti, Giovanni, Lewis, Caroline A., Puissant, Alexandre, Vander Heiden, Matthew G., Stegmaier, Kimberly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807390/
https://www.ncbi.nlm.nih.gov/pubmed/34341479
http://dx.doi.org/10.1038/s41375-021-01361-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807390/
https://www.ncbi.nlm.nih.gov/pubmed/34341479
http://dx.doi.org/10.1038/s41375-021-01361-8

Ejemplares similares